[go: up one dir, main page]

NO991524D0 - vaccinations - Google Patents

vaccinations

Info

Publication number
NO991524D0
NO991524D0 NO991524A NO991524A NO991524D0 NO 991524 D0 NO991524 D0 NO 991524D0 NO 991524 A NO991524 A NO 991524A NO 991524 A NO991524 A NO 991524A NO 991524 D0 NO991524 D0 NO 991524D0
Authority
NO
Norway
Prior art keywords
vaccinations
Prior art date
Application number
NO991524A
Other languages
Norwegian (no)
Other versions
NO991524L (en
Inventor
Nathalie Garcon
Martin Friede
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of NO991524D0 publication Critical patent/NO991524D0/en
Publication of NO991524L publication Critical patent/NO991524L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
NO991524A 1996-10-05 1999-03-29 vaccinations NO991524L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9620795.6A GB9620795D0 (en) 1996-10-05 1996-10-05 Vaccines
PCT/EP1997/005578 WO1998015287A1 (en) 1996-10-05 1997-09-30 Vaccines

Publications (2)

Publication Number Publication Date
NO991524D0 true NO991524D0 (en) 1999-03-29
NO991524L NO991524L (en) 1999-03-29

Family

ID=10800990

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991524A NO991524L (en) 1996-10-05 1999-03-29 vaccinations

Country Status (19)

Country Link
EP (1) EP0939650A1 (en)
JP (1) JP2001501640A (en)
KR (1) KR20000048866A (en)
CN (1) CN1238696A (en)
AR (1) AR009958A1 (en)
AU (1) AU714930B2 (en)
BR (1) BR9711853A (en)
CA (1) CA2267191A1 (en)
CO (1) CO4910170A1 (en)
CZ (1) CZ116799A3 (en)
GB (1) GB9620795D0 (en)
HU (1) HUP9904549A3 (en)
IL (1) IL128985A0 (en)
NO (1) NO991524L (en)
NZ (1) NZ334734A (en)
PL (1) PL332633A1 (en)
TR (1) TR199900729T2 (en)
WO (1) WO1998015287A1 (en)
ZA (1) ZA978868B (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2500490T3 (en) * 1997-08-29 2014-09-30 Antigenics Inc. Compositions comprising adjuvant QS-21 and polysorbate or cyclodextrin as excipient
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
CN100406060C (en) * 1998-10-16 2008-07-30 史密丝克莱恩比彻姆生物有限公司 Adjuvant composition
JP3282603B2 (en) 1999-01-28 2002-05-20 株式会社微生物化学研究所 Adjuvants and vaccines using them
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
CN1227030C (en) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 Adjuvant compositions comprising saponins and immunostimulatory oligonucleotides
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
PL353791A1 (en) 1999-09-24 2003-12-01 Nihon Nohyaku Co, Ltd.Nihon Nohyaku Co, Ltd. Aromatic diamide derivatives or salts thereof, agricultural/horticultural chemicals and method of using the same
EP1227837B1 (en) 1999-10-22 2008-05-21 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
DE60039715D1 (en) * 1999-11-19 2008-09-11 Csl Ltd HCV VACCINE COMPOSITIONS
WO2001041802A1 (en) * 1999-12-08 2001-06-14 Statens Veterinärmedicinska Anstalt Vaccine adjuvants comprising ginseng plant extract and added aluminium salt
US6905712B2 (en) 1999-12-08 2005-06-14 Statens Veterinarmedicinska Anstalt Vaccine adjuvants comprising ginseng plant extract and added aluminum salt
ATE513913T1 (en) 2000-05-10 2011-07-15 Sanofi Pasteur Ltd IMMUNOGENIC POLYPEPTIDES ENCODED BY MAGE MINIGENE AND USES THEREOF
PT1326638E (en) 2000-10-18 2008-02-06 Glaxosmithkline Biolog Sa Vaccines against cancers
WO2002067983A1 (en) * 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
ATE503493T1 (en) * 2001-02-23 2011-04-15 Glaxosmithkline Biolog Sa INFLUENZA VACCINE COMPOSITIONS FOR INTRADERMAL ADMINISTRATION
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
CA2484941A1 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
CA2484339A1 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
CA2502268A1 (en) 2002-10-23 2004-05-06 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
AU2004224747A1 (en) * 2003-03-24 2004-10-07 Intercell Ag Use of Alum and a th1 immune response inducing adjuvant for enhancing immune responses
CA2517673C (en) 2003-03-24 2013-08-13 Intercell Ag Improved vaccines for preventing viral infection
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
PL1945252T3 (en) 2005-11-04 2013-11-29 Seqirus Uk Ltd Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene
TWI457133B (en) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
PT1973564T (en) 2005-12-22 2017-01-24 Glaxosmithkline Biologicals Sa Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
BRPI0710210A2 (en) 2006-03-30 2011-05-24 Glaxomithkline Biolog S A immunogenic composition, vaccine, methods for preparing the vaccine, and for preventing or treating staphylococcal infection, use of the immunogenic composition, and process for conjugating oligosaccharide or capsular polysaccharide
WO2008009652A2 (en) 2006-07-18 2008-01-24 Glaxosmithkline Biologicals S.A. Vaccines for malaria
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
AU2007322424B2 (en) * 2006-11-20 2013-05-16 Duecom Use of lipid containing particles comprising quillaja saponins for the treatment of cancer
CN101675068A (en) 2007-03-02 2010-03-17 葛兰素史密丝克莱恩生物有限公司 Novel methods and compositions
AU2008267208B2 (en) 2007-06-26 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
MX2010001752A (en) 2007-08-13 2010-03-10 Glaxosmithkline Biolog Sa Vaccines.
WO2009117035A1 (en) 2007-12-19 2009-09-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
US9278126B2 (en) 2009-02-10 2016-03-08 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
CA2754533C (en) * 2009-03-05 2019-07-09 Jenny Colleen Mccloskey Treatment of infection
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2552480A1 (en) 2010-03-26 2013-02-06 GlaxoSmithKline Biologicals S.A. Hiv vaccine
WO2012038801A1 (en) 2010-09-21 2012-03-29 National Institute Of Immunology A spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
SI2758432T1 (en) 2011-09-16 2019-07-31 Ucb Biopharma Sprl Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
US11498956B2 (en) 2016-08-23 2022-11-15 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain(CD74)
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
WO2018060288A1 (en) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
CA3045952A1 (en) * 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Novel process
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
US12527742B2 (en) 2017-05-30 2026-01-20 Glaxosmithkline Biologicals S.A. Methods for manufacturing a liposome encapsulated RNA
IE87414B1 (en) * 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
MX2020013553A (en) 2018-06-12 2021-02-26 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides.
CA3107077A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
WO2020128012A1 (en) 2018-12-21 2020-06-25 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
CN113573730A (en) 2019-03-05 2021-10-29 葛兰素史密斯克莱生物公司 Hepatitis B immunization protocols and compositions
EP4021407A1 (en) 2019-08-30 2022-07-06 GlaxoSmithKline Biologicals S.A. Jet mixing lipid nanoparticle manufacturing process
WO2023056117A1 (en) * 2021-10-02 2023-04-06 Massachusetts Institute Of Technology Synergistic combination of alum and non-liposome, non-micelle particle vaccine adjuvants
EP4637812A1 (en) 2022-12-19 2025-10-29 GlaxoSmithKline Biologicals S.A. Hepatitis b compositions
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002314A (en) * 1990-10-23 1992-05-18 Nederlanden Staat IMMUNOGENE COMPLEXES, IN PARTICULAR ISCOMS.
PH30906A (en) * 1991-07-25 1997-12-23 Idec Pharma Corp Induction of cytotoxic t-lymphocyte responses.
ES2199227T5 (en) * 1993-03-29 2007-12-01 Pfizer Inc. MULTICOMPONENT CLOSTRIDIAL VACCINES USING SAPONINA ASSISTANTS.
UA56132C2 (en) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine

Also Published As

Publication number Publication date
EP0939650A1 (en) 1999-09-08
HU9904549A (en) 2000-05-28
TR199900729T2 (en) 1999-07-21
KR20000048866A (en) 2000-07-25
CA2267191A1 (en) 1998-04-16
WO1998015287A1 (en) 1998-04-16
CZ116799A3 (en) 1999-08-11
AU714930B2 (en) 2000-01-13
HUP9904549A3 (en) 2001-06-28
CO4910170A1 (en) 2000-04-24
NZ334734A (en) 2000-05-26
AU4781297A (en) 1998-05-05
BR9711853A (en) 1999-08-24
PL332633A1 (en) 1999-09-27
NO991524L (en) 1999-03-29
ZA978868B (en) 1999-04-06
JP2001501640A (en) 2001-02-06
GB9620795D0 (en) 1996-11-20
CN1238696A (en) 1999-12-15
IL128985A0 (en) 2000-02-17
AR009958A1 (en) 2000-05-17

Similar Documents

Publication Publication Date Title
NO991524D0 (en) vaccinations
ID21031A (en) KORNEA MADE
DE69714798D1 (en) Blutentnahmröhrchen
DE69736584D1 (en) Benutzereingabeabtastvorrichtung
ID18090A (en) MICROCAPSUL USING IMINOOKSADIAZINADIONA POLYISOSIANAT
NO984120D0 (en) Triarylforbindelser
DE69734622D1 (en) Leitstrahlrichtungseinstellvorrichtung
ATE208395T1 (en) THIOPHENOPYRIMIDINES
NO984058D0 (en) Quinoksalindioner
DE69631845D1 (en) MUSTEREXTRAHIERUNGSGERÄT
FI961556A0 (en) Luftavskiljare
NO983508D0 (en) Antiglukortikoidmedikament
DE69716524D1 (en) Crimpsteckverbindungsbuchse
KR970007831U (en) Kimbap using kimbap
NO980721D0 (en) vaccinations
FI961889A0 (en) Axialkolvmaskin
SE9600402L (en) Retaining
FI2888U1 (en) PAALILEIKKURI
IT1288896B1 (en) CAP-GLASS
FI960763A0 (en) Vattenkraftverk
BR7603492U (en) Protemilk
NO960406D0 (en) Bevanningsanordning
BR7601720U (en) Paraglayder
BR9606119A (en) Heliceboy
FI960814A0 (en) Piskstaellning

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application